Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 12, Issue 10, Pages 1069-1089Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1744666X.2016.1191351
Keywords
Multiple sclerosis; demyelination; immune therapies
Categories
Funding
- Biogen Idec
- TEVA Pharmaceuticals
Ask authors/readers for more resources
Introduction: The understanding of the immunopathogenesis of multiple sclerosis (MS) has expanded with more research into T-cell subtypes, cytokine contributors, B-cell participation, mitochondrial dysfunction, and more. Treatment options have rapidly expanded with three relatively recent oral therapy alternatives entering the arena.Areas covered: In the following review, we discuss current mechanisms of immune dysregulation in MS, how they relate to current treatments, and the impact these findings will have on the future of therapy.Expert commentary: The efficacy of these medications and understanding their mechanisms of actions validates the immunopathogenic mechanisms thought to underlie MS. Further research has exposed new targets, while new promising therapies have shed light on new aspects into the pathophysiology of MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available